Clinical Trials Logo

BRAF Gene Mutation clinical trials

View clinical trials related to BRAF Gene Mutation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04488003 Terminated - Clinical trials for Advanced Solid Tumor

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Start date: January 7, 2021
Phase: Phase 2
Study type: Interventional

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.

NCT ID: NCT01907802 Terminated - Renal Failure Clinical Trials

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Start date: August 23, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.